Long-term immunogenicity of inactivated hepatitis A vaccine: Follow-up at 15 years

Journal of Pediatric Infectious Diseases

Volumn 5, Issue 4, 2010, Pages 321-326

  Byrd, Kathy K ^a,b   Bruden, Dana L ^a   Bruce, Michael G ^a   Bulkow, Lisa R ^a   Zanis, Carolyn L ^a   Snowball, Mary M ^c   Homan, Chriss E ^c   Hennessy, Thomas W ^a   Williams, James L ^c   Dunaway, Eitel ^a   Chaves, Sandra S ^d   McMahon, Brian J ^a,c  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^c Liver Disease and Hepatitis Program   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Hepatitis A; immunogenicity; inactivated hepatitis A vaccine

Indexed keywords

HEPATITIS A VACCINE; INACTIVATED VIRUS VACCINE;

ADOLESCENT; ARTICLE; CHILD; FEMALE; HEPATITIS A; HEPATITIS A VIRUS; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; SEROLOGY; TREATMENT DURATION; VACCINATION; VIRUS IMMUNITY;

EID: 78650450299     PISSN: 13057707     EISSN: None     Source Type: Journal    
DOI: 10.3233/JPI-2010-0269     Document Type: Article

References (22)

1. R.S. Koff and A. Hepatitis, Lancet 351 (1998), 1643-1649.
2. A. Wasley, S. Grytdal and K. Gallagher, Centers for Disease Control and Prevention (CDC). Surveillance for acute viral hepatitis-United States, 2006, MMWR Surveill Summ 57 (2008), 1-24.
3. Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. W. Atkinson, S. Wolfe, J. Hamborsky, L. McIntyre, eds, (11th ed).Washington DC: Public Health Foundation, 2009.
4. Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR Recomm Rep 45(RR-15) (1996), 1-30.
5. D. Peach, B.J. McMahon, L. Bulkow, E. Funk, R. Harpaz and H.S. Margolis, Impact of recurrent epidemics of hepatitis a virus infection on population immunity levels: Bristol Bay, Alaska, J Infect Dis 186 (2002), 1081-1085.
6. B.J. McMahon, M. Beller, J.Williams, M. Schloss, H. Tanttila and L. Bulkow, A program to control an outbreak of hepatitis A in Alaska by using an inactivated hepatitis A vaccine, Arch Pediatr Adolesc Med 150 (1996), 733-739.
7. L.R. Bulkow, R.B. Wainwright, B.J. McMahon, J.P. Middaugh, S.A. Jenkerson and H.S. Margolis, Secular trends in hepatitis A virus infection among Alaska Natives, J Infect Dis 168 (1993), 1017-1020.
8. Advisory Committee on Immunization Practices (ACIP), A.E. Fiore, A. Wasley and B.P. Bell, Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR Recomm Rep 55(RR-7) (2006), 1-23.
9. A. Wasley, J.T. Miller and L. Finelli, Centers for Disease Control and Prevention (CDC). Surveillance for acute viral hepatitis-United States, 2005, MMWR Surveill Summ 56 (2007), 1-24.
10. S.R. Bialek, D.A. Thoroughman, D. Hu et al., Hepatitis A incidence and hepatitis a vaccination among American Indians and Alaska Natives, 1990-2001, Am J Public Health 94 (2004), 996-1001.
11. B.J. McMahon, J.Williams, L. Bulkow et al., Immunogenicity of an inactivated hepatitis A vaccine in Alaska Native children and Native and non-Native adults, J Infect Dis 171 (1995), 676-679.
12. L.L. Hammitt, L. Bulkow, T.W. Hennessy et al., Persistence of antibody to hepatitis A virus 10 years after vaccination among children and adults, J Infect Dis 198 (2008), 1776-1782.
13. P.J. Provost and M.R. Hilleman, An inactivated hepatitis A virus vaccine prepared from infected marmoset liver, Proc Soc Exp Biol Med 159 (1978), 201-203.
14. P. Van Damme and K. Van Herck, Effect of hepatitis A vaccination programs, JAMA 294 (2005), 246-248.
15. Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR Recomm Rep 48(RR-12) (1999), 1-37.
16. P. Van Damme, J. Banatvala, O. Fay et al., Hepatitis A booster vaccination: is there a need? Lancet 362 (2003), 1065-1071.
17. C.Y. Chan, S.D. Lee, M.I. Yu, Y.J. Wang, F.Y. Chang and K.J. Lo, Long-term follow-up of hepatitis A vaccination in children, Vaccine 17 (1999), 369-372.
18. P.C. Fan, M.H. Chang, P.I. Lee, A. Safary and C.Y. Lee, Follow-up immunogenicity of an inactivated hepatitis A virus vaccine in healthy children: results after 5 years, Vaccine 16 (1998), 232-235.
19. K. Van Herck and P. Van Damme, Inactivated hepatitis A vaccine-induced antibodies: follow-up and estimates of longterm persistence, J Med Virol 63 (2001), 1-7.
20. B.P. Bell, S. Negus, A.E. Fiore et al., Immunogenicity of an inactivated hepatitis A vaccine in infants and young children, Pediatr Infect Dis J 26 (2007), 116-122.
21. K. Abarca, I. Ibánez, C. Perret, P. Vial and J.A. Zinsou, Immunogenicity, safety, and interchangeability of two inactivated hepatitis A vaccines in Chilean children, Int J Infect Dis 12 (2008), 270-277.
22. J. Williams, L. Fox-Leyva, C. Christensen et al. Hepatitis A vaccine administration: comparison between jet-injector and needle injection, Vaccine 18 (2000), 1939-1943.